Breast cancer immunotherapy: current status and future prospects

Area of Science:

• Immunology
• Oncology
• Vaccine Development

Background:

• Cancer immunotherapy faces challenges in eliciting effective anti-tumor immune responses.
• Mucins, like Mucin1 (MUC1), are overexpressed and altered in various cancers (e.g., breast, pancreas, ovary), making them potential targets.
• Tumor-specific MUC1 is characterized by overexpression, altered glycosylation, and aberrant cell surface localization.

Purpose of the Study:

• To explore MUC1 as a target for cancer immunotherapy, specifically for breast cancer vaccines.
• To investigate the potential of mannan as a carrier for MUC1-based vaccines.
• To evaluate the immunogenicity and suitability of MUC1-mannan conjugates for cancer immunotherapy.

Main Methods:

• Development of immunotherapeutic strategies targeting MUC1 using synthetic carbohydrates or peptides conjugated to carriers.
• Utilizing mannan, a polymannose carbohydrate from yeast, as a protein carrier.
• Investigating different mannan conjugation modes (oxidized or reduced) to modulate immune response (T1-type cellular or T2-type humoral).

Main Results:

• Mannan serves as an effective carrier for MUC1, capable of eliciting either a cellular or humoral immune response based on conjugation method.
• MUC1's tumor-specific characteristics make it a viable target for vaccine development.
• Ongoing clinical trials are assessing the immunogenicity of MUC1 and its potential in breast cancer immunotherapy.

Conclusions:

• MUC1 is a viable target for cancer immunotherapy, especially in breast cancer.
• Mannan is a versatile and effective carrier for MUC1-based vaccines, with tunable immune responses.
• Further clinical evaluation is necessary to establish MUC1-mannan vaccines for cancer treatment.